Insmed sells lung-disease treatments with a big new launch (brensocatib).
Insmed Incorporated (INSM) is expected to report earnings on Thursday, October 29, 2026, before the open. Estimated release time 07:00 ET. Consensus EPS estimate is $-0.39.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | Jun 2026 qtr | $-0.67 | $-0.06 | — | $425.49M |
| 2026-05-07 | Mar 2026 qtr | $-0.96 | $-0.76 | — | $305.96M |
| 2026-02-19 | Dec 2025 qtr | $-1.07 | $-1.54 | — | $263.84M |
| 2025-10-30 | Sep 2025 qtr | $-1.33 | $-1.75 | — | $142.34M |
| 2025-08-07 | Jun 2025 qtr | $-1.30 | $-1.70 | — | $107.42M |
| 2025-05-08 | Mar 2025 qtr | $-1.34 | $-1.42 | -6.0% | $92.82M |
| 2025-02-20 | Dec 2024 qtr | $-1.17 | $-1.32 | -12.8% | $104.44M |
| 2024-10-31 | Sep 2024 qtr | $-1.20 | $-1.27 | -5.8% | $93.42M |
INSM has beaten consensus EPS in 0 of its last 3 scored quarters.
See INSM on the live calendar →